Financial Performance and Results
Cipla Limited reported standalone revenue of ₹19,044.85 crores and profit after tax of ₹3,515.18 crores for FY 2025-26. The Board recommended a final dividend of ₹13 per equity share (650% on face value of ₹2), subject to approval at the 90th Annual General Meeting. The total dividend payout amounts to approximately ₹1,050.12 crores, representing 29.87% of standalone profit after tax. Consolidated financial statements showed revenue from operations of ₹27,711.69 crores across business units: India (₹12,679.44 Cr), North America (₹6,862.12 Cr), South Africa & Africa (₹4,285.43 Cr), Emerging Markets (₹2,062.07 Cr), Europe (₹1,493.18 Cr), and API & Others (₹329.45 Cr).
Corporate Governance and Board Changes
Significant management changes occurred with Mr. Umang Vohra completing his second term as MD & CEO and resigning effective 1st April 2026. Mr. Achin Gupta was appointed as Managing Director & Global Chief Executive Officer for a five-year term from 1st April 2026. Mr. P R Ramesh was re-appointed as Independent Director for a second term, while Mr. Robert Stewart did not seek re-appointment upon completion of his first term. The Board approved appointment of M/s B S R & Co. LLP as new Statutory Auditors for a five-year term following the completion of Walker Chandiok & Co LLP's second term.
Annual General Meeting and Corporate Actions
The 90th Annual General Meeting is scheduled for 25th June 2026 at 2:00 p.m. IST through video conferencing only. Six resolutions will be presented including adoption of financial statements, dividend declaration, reappointment of Mr. Adil Zainulbhai as Non-Executive Director, appointment of statutory auditors, and ratification of cost auditor remuneration. Remote e-voting will be available from 21st to 24th June 2026 through NSDL platform. The record date for dividend entitlement is set for 5th June 2026.
Strategic Initiatives and Subsidiary Updates
The Board approved a Scheme of Amalgamation for wholly-owned subsidiary Inzpera Healthsciences Limited with Cipla Limited, with appointed date of 1st April 2026, subject to NCLT approval. The company maintained 44 subsidiaries and 10 associates as of 31st March 2026, including significant entities like Cipla USA Inc., InvaGen Pharmaceuticals Inc., and Cipla Medpro South Africa. Three newly incorporated subsidiaries had not commenced operations during the year. Investments in associates totaled ₹266.04 crores, with Stempeutics Research being the largest at ₹80.28 crores.
Compliance and Sustainability Reporting
The company complied with all SEBI Listing Regulations and Companies Act requirements. Secretarial Audit Report contained no qualifications or adverse remarks. DNV Business Assurance provided independent limited assurance on sustainability disclosures in the Integrated Report and BRSR for FY 2025-26, covering GRI Standards, Integrated Reporting Framework, and UN SDGs. The assurance concluded that disclosures were fairly stated and prepared in accordance with reporting criteria.
Asset Position and Accounting Policies
Property, plant and equipment stood at ₹8,105.56 crores (gross) and ₹3,631.03 crores (net) on standalone basis, while consolidated figures were ₹11,766.71 crores (gross) and ₹5,586.66 crores (net). Intangible assets included significant acquisitions: Galvus trademark (₹1,107.28 crores), Doloneuron and Zolsoma (₹101.18 crores), and Yurpeak marketing rights (₹90.26 crores). Goodwill on consolidation amounted to ₹3,754.42 crores allocated to CGUs in United States (₹2,294.66 Cr), South Africa (₹1,290.78 Cr), and Others (₹168.98 Cr). Financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) with comprehensive accounting policies covering revenue recognition, leases, employee benefits, and impairment assessments.